Beta Blockers - A Comprehensive Overview

1. Mechanism of Action

Beta blockers competitively antagonize catecholamines (epinephrine, norepinephrine) at beta-adrenoceptors. Most are pure antagonists - they occupy the receptor without activating it. Some are partial agonists with intrinsic sympathomimetic activity (ISA), which moderately activates receptors in the absence of endogenous agonists but blocks them when catecholamine levels are high.

Beta receptors relevant to pharmacology:

β1 - heart (↑ HR, ↑ contractility, ↑ conduction velocity), kidney (↑ renin release)
β2 - bronchial smooth muscle (relaxation), vascular smooth muscle (vasodilation), uterus, liver (glycogenolysis)
β3 - adipose tissue (lipolysis)

Blocking these receptors produces the opposite effects: decreased heart rate (negative chronotropy), decreased contractility (negative inotropy), slowed AV conduction, and decreased renin release.

2. Classification

By Receptor Selectivity

Category	Drugs	Key Feature
Non-selective (β1 + β2)	Propranolol, nadolol, timolol, sotalol, pindolol, carteolol	Block both β1 and β2; risk of bronchoconstriction
β1-selective (cardioselective)	Metoprolol, atenolol, bisoprolol, betaxolol, acebutolol, nebivolol	Preferentially block β1; safer in asthma/COPD at low doses
α + β blockers	Carvedilol, labetalol	Block α1 as well → additional vasodilation

Note: Selectivity is dose-dependent - at high doses, β1-selective agents also block β2 receptors.

By Additional Properties

Property	Drugs	Clinical Relevance
ISA (partial agonist activity)	Pindolol, acebutolol, penbutolol	Less resting bradycardia and less cold extremities; overdose may cause tachycardia
Membrane-stabilizing activity (MSA)	Propranolol, acebutolol	Sodium channel blockade; relevant in overdose
Lipophilic	Propranolol, metoprolol, carvedilol	CNS penetration, hepatic metabolism, short half-life
Hydrophilic	Atenolol, nadolol	Renal excretion, longer half-life, less CNS effects
Ultra-short acting (IV)	Esmolol	t½ ~9 min; metabolized by red blood cell esterases
Vasodilating (β3/NO)	Nebivolol	Releases NO, additional vasodilation

3. Pharmacokinetics

Propranolol: highly lipophilic, extensive first-pass hepatic metabolism, t½ ~4 h, CNS penetration
Metoprolol: moderate lipophilicity, hepatic metabolism (CYP2D6), available as tartrate (short-acting) and succinate (extended-release)
Atenolol: hydrophilic, renally excreted, t½ ~6-7 h, minimal CNS effects
Carvedilol: hepatic metabolism, non-selective with α1 blockade
Esmolol: IV only, t½ ~9 min, metabolized by esterases in RBCs - ideal for intraoperative/ICU control

4. Clinical Indications

Cardiovascular

Hypertension - reduce cardiac output and renin secretion; effective but not first-line as monotherapy per current guidelines
Heart failure with reduced EF (HFrEF) - three agents with proven mortality benefit: bisoprolol, metoprolol succinate (MERIT-HF, CIBIS II), and carvedilol (COPERNICUS, CAPRICORN). Therapy is biphasic: short-term negative inotropy followed by long-term reverse remodeling with improved LVEF, reduced hospitalizations, and prolonged survival. Must be initiated at low doses, up-titrated slowly (no sooner than every 2 weeks), and started only when the patient is euvolemic. - Braunwald's Heart Disease
Ischemic heart disease / stable angina - reduce myocardial oxygen demand (↓ HR, ↓ contractility); also relieve exercise-induced angina
Post-MI - reduce mortality and sudden death (propranolol, metoprolol, carvedilol)
Arrhythmias - AF rate control, SVT, ventricular arrhythmias; sotalol also has class III antiarrhythmic activity
Aortic dissection - labetalol or IV metoprolol/esmolol to control HR and BP urgently

Other

Glaucoma - topical timolol, betaxolol (reduce aqueous humor production)
Hyperthyroidism / thyroid storm - propranolol blocks peripheral T4→T3 conversion in addition to sympathetic effects; controls tachycardia and tremor
Pheochromocytoma - used AFTER adequate alpha blockade (never before, to prevent hypertensive crisis from unopposed α stimulation)
Portal hypertension / esophageal varices prophylaxis - non-selective agents (propranolol, nadolol) reduce portal pressure
Migraine prophylaxis - propranolol, metoprolol, atenolol
Essential tremor - propranolol
Anxiety (situational/performance) - propranolol
HOCM - reduce LV outflow obstruction

5. Adverse Effects

Effect	Mechanism
Bradycardia, heart block	β1 blockade in the heart
Fatigue, exercise intolerance	↓ cardiac output
Bronchoconstriction	β2 blockade in airways (especially non-selective)
Cold extremities, Raynaud exacerbation	β2 blockade in peripheral vasculature
Impaired glycemic awareness	Masks tachycardia/tremor of hypoglycemia (not sweating); caution in insulin-dependent diabetes
Hyperkalemia	↓ β2-mediated K+ uptake into cells
CNS effects (lipophilic agents)	Depression, nightmares, fatigue (propranolol)
Dyslipidemia	↑ triglycerides, ↓ HDL (less with cardioselective agents)
Worsening HF initially	Negative inotropy; overcome with slow titration

6. Contraindications

Absolute: Cardiogenic shock, decompensated acute HF, high-degree AV block (unless pacemaker in place), severe bradycardia, sick sinus syndrome
Relative: Reactive airways disease (use cardioselective agents with caution if unavoidable), insulin-dependent diabetes, severe peripheral arterial disease

7. Drug Withdrawal

Abrupt withdrawal can precipitate rebound tachycardia, angina, and even MI due to up-regulation of beta receptors during chronic blockade. Doses should always be tapered gradually over 1-2 weeks.

8. Overdose

Most toxic: propranolol (MSA + lipophilicity)
As little as 2-3x the therapeutic dose can be dangerous
Manifestations: bradycardia, hypotension, wide QRS (with propranolol), seizures
Agents with ISA (e.g., pindolol) overdose may paradoxically cause tachycardia/hypertension
Standard resuscitation (fluids, atropine, beta-agonists) is often ineffective
Glucagon 5-10 mg IV is the antidote - raises intracellular cAMP independently of beta receptors; it is the drug of choice for beta blocker overdose
High-dose insulin therapy and lipid emulsion are additional rescue options in refractory cases

9. Key Individual Drugs

Drug	Key Features
Propranolol	Prototype; non-selective, lipophilic, MSA; also used in thyrotoxicosis, migraine, varices, tremor
Metoprolol	β1-selective; tartrate (twice daily) vs. succinate (once daily, preferred in HF)
Atenolol	β1-selective, hydrophilic, once daily; less CNS effects
Bisoprolol	β1-selective; proven mortality benefit in HFrEF
Carvedilol	Non-selective + α1 blocker; proven in HFrEF; also vasodilates
Labetalol	α1 + β1 + β2 blocker; IV use in hypertensive urgency, aortic dissection, eclampsia; safe in pregnancy
Esmolol	IV only, ultra-short t½; intraoperative tachycardia/arrhythmia
Nebivolol	β1-selective + NO-mediated vasodilation; metabolic neutrality
Sotalol	Non-selective β blocker + class III antiarrhythmic (K+ channel block); prolongs QT; used in AF/VT
Timolol	Non-selective; ophthalmic drops for glaucoma; also oral for HTN/post-MI
Acebutolol	β1-selective, with ISA; less bradycardia at rest
Pindolol	Non-selective, strong ISA; least bradycardia

Sources: Katzung's Basic and Clinical Pharmacology, 16th Ed., Chapter 10 | Braunwald's Heart Disease, Chapter 50

This is a shared conversation. Sign in to Orris to start your own chat.